Marker Therapeutics, Inc.
MRKRHealthcare|Biotechnology|US
$0.89
-0.00 (-0.30%)
DCF Value
$1.08
Tangible Book / Share
$0.63
Cash / Share
$0.59
Clinical Trials (21)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05798897 Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory | P1 | Recruiting | 79 | Open-label | MT-601 |
| NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS | Acute Myeloid Leukemia, in Relapse, MDS | P1 | Recruiting | 40 | Open-label | MT-401-OTS |
| NCT07560579 Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity | Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure | N/A | Active | 226 | RCT, Single-blind | — |
| NCT06703632 Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection | Screening for Colon Cancer, Blood Samples | N/A | Recruiting | 4,538 | Open-label | — |
| NCT06889844 Observational Cross-reactivity Study for Colorectal Cancer Diagnosis | Colorectal Cancer | Recruiting | 250 | — | — | |
| NCT06696534 Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme | Screening for Colon Cancer, Survey and Questionnaire | N/A | Recruiting | 1,000 | Open-label | — |
| NCT06889883 Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer | Colorectal Carcinoma, Advanced Adenomas (AA) | Recruiting | 510 | — | — | |
| NCT04511130 Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant | Acute Myeloid Leukemia, Stem Cell Transplantation | P2 | Terminated | 92 | RCT, Open-label | MT-401 |
| NCT02593227 Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | Breast Cancer | P2 | Completed | 80 | RCT, Open-label | Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine |
| NCT02978222 Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | Platinum Sensitive Ovarian Cancer, Ovarian Cancer | P2 | Terminated | 120 | RCT, Double-blind | FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone |
| NCT02764333 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Ovarian Cancer | P2 | Completed | 29 | Open-label | TPIV200, Durvalumab |
| NCT01632332 Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | HER2-positive Breast Cancer, Male Breast Cancer | P1 | Completed | 22 | Open-label | HER-2/neu peptide vaccine |
| NCT06549751 MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Pancreas Cancer, Pancreatic Cancer Metastatic | P1 | Not Yet Recruiting | 38 | Open-label | MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells, MT-601 dose 1200 million cells |
| NCT06864377 Ventral Hernia Improvement of Treatment and Life | Incisional Hernia, Parastomal Hernia | By Invite | 300 | — | — | |
| NCT07461857 Minority-focused Environmental Health Education and Tracking Pilot Study | Environmental Exposure | N/A | Completed | 151 | Open-label | — |
| NCT07703046 Sperm, Exposure and Endocrine Disruptors | Fertility, Male Fertility | N/A | Not Yet Recruiting | 100 | RCT, Single-blind | — |
| NCT05780047 Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age | Endocrine Disrupting Chemicals, Environmental Exposure | N/A | Completed | 434 | Open-label | — |
| NCT07391397 Assessing PFAS Exposure for Better Health | Environmental Health Effects | N/A | Completed | 183 | Open-label | — |
| NCT04358003 Plasma Adsorption in Patients With Confirmed COVID-19 | Respiratory Failure, ARDS | N/A | Completed | 107 | Open-label | — |
| NCT06450951 A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals | Environmental Exposure | N/A | Completed | 1,074 | RCT, Single-blind | — |
| NCT06738511 Validation of a Molecular Signature for Early Detection of Colorectal Cancer | Colorectal Cancer Screening, Advanced Adenomas (AA) | N/A | Completed | 3,421 | Open-label | — |